source
- Venture funding for women’s health startups drops sharply after 2024 peak, AI may drive reboundVenture capital flowing into women’s health companies fell sharply after reaching record levels in 2024. A Silicon Valley Bank report shows total funding dropped from about $3.2 billion in 2024 to…
- Curium seeks FDA review of rival radioligand therapy to boost supply resilience against Novartis' PluvictoCurium is preparing to challenge Novartis' dominant prostate cancer radioligand therapy, Pluvicto, by entering discussions with the FDA about reviewing its own PSMA‑directed Lu‑177 candidate. Nova…